Saturday 17 October 2026
Export OMER’s income statement to Excel — free account
Omeros Corporation
OMER Healthcare Biotechnology
In the quarter to June 2026, revenue grew 35.5%, EPS grew 141.9%, free cash flow grew 118.7% and total debt fell 42.0%, each against the same quarter a year earlier.
16.20
2.59
−13.78%
Follow OMER
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 1 | 4 | 2 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/S ratio |
9.82 | 14.16 | 18.12 | 6.24 | 11.07 | — | — | — | — | — |
Altman Z-Score |
(8.73) | (1.68) | (10.72) | (8.09) | (6.82) | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(24.26) | (12.60) | (26.90) | (22.80) | (17.81) | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Beneish M-Score |
(2.25) | (2.79) | (3.11) | (0.06) | — | — | — | — | — | — |
P/Operating CF |
(37.61) | (220.05) | (21.95) | (30.32) | (44.39) | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Sales |
10.64 | 14.16 | 21.08 | 7.14 | 12.49 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
(8.60) | (25.33) | (6.07) | (13.30) | (9.21) | — | — | — | — | — |
EV/FCF |
(8.57) | (25.09) | (6.04) | (13.22) | (9.19) | — | — | — | — | — |
Quick Ratio |
3.57 | 3.84 | 2.23 | 1.73 | 3.78 | 3.77 | 2.99 | 3.38 | 1.23 | 2.34 |
Current Ratio |
3.75 | 4.12 | 2.41 | 1.87 | 4.12 | 4.79 | 3.25 | 4.09 | 1.69 | 2.76 |
Net Debt/EBITDA |
(0.64) | 0.00 | (0.80) | (0.70) | (0.68) | (0.94) | (0.75) | (0.26) | (0.57) | (0.30) |
Debt/Assets |
118.48% | 72.04% | 156.22% | 118.07% | 132.60% | 76.02% | 53.35% | 56.35% | 67.70% | 64.04% |
Debt/Equity |
(2.13) | (29.78) | (1.50) | (1.48) | (1.99) | 13.40 | 3.68 | (8.53) | (1.03) | (1.72) |
Asset Turnover |
0.72 | 0.71 | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.77 | 0.68 | 0.82 | 0.71 | 0.72 | (0.56) | (1.82) | (0.63) | 0.95 | 34.65 |
Capex/Depreciation |
(0.42) | (0.64) | (0.59) | (0.19) | (0.18) | (0.20) | (0.04) | (0.15) | 0.06 | 0.10 |
Interest Coverage |
(6.94) | (3.98) | (6.91) | (6.45) | (5.87) | (8.83) | (7.20) | (5.33) | (6.77) | 127.91 |
| 209.62% | 265.67% | 246.20% | 80.78% | 120.17% | (400.60%) | 86.63% | (388.17%) | 151.08% | 2.21% | |
| (114.81%) | (58.26%) | (119.43%) | (72.55%) | (86.83%) | 64.71% | 9.39% | (24.31%) | (47.86%) | (1.11%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (58.58%) | (49.56%) | (629.94%) | 0.00% | 0.00% |
Return on Tangible Assets |
(147.11%) | (63.53%) | (224.92%) | (162.11%) | (117.90%) | 98.15% | 15.38% | (70.74%) | (273.81%) | (2.40%) |
Average Days of Receivables |
105.57 | 96.53 | 278.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
121.82% | 85.77% | 300.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
105.20% | 80.28% | 173.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
32.64% | 19.57% | 39.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.11) | (0.01) | (0.20) | (0.20) | (0.18) | — | — | — | — | — |
Graham Number |
5.86 | 1.28 | 11.00 | 9.18 | 10.68 | — | — | — | — | — |
Earnings Yield |
(16.34%) | (5.80%) | (23.43%) | (12.07%) | (16.79%) | — | — | — | — | — |
Free Cash Flow Yield |
(12.65%) | (3.98%) | (19.27%) | (8.66%) | (12.28%) | — | — | — | — | — |
Revenue per Share |
1.03 | 1.42 | 0.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.27) | (0.80) | (2.14) | (1.21) | (1.75) | (1.76) | (1.38) | 1.19 | (2.56) | (1.83) |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.28) | (0.80) | (2.15) | (1.22) | (1.76) | (1.76) | (1.38) | 1.18 | (2.56) | (1.83) |
Cash per Share |
1.12 | 1.84 | 1.25 | 1.23 | 2.36 | 2.52 | 3.11 | 2.74 | 1.55 | 2.71 |
Shareholders Equity per Share |
(0.93) | (0.06) | (2.06) | (2.20) | (2.11) | 0.38 | 1.37 | (0.40) | (3.14) | (1.91) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.93) | (0.06) | (2.06) | (2.20) | (2.11) | 0.38 | 1.37 | (0.40) | (3.14) | (1.91) |
Free Cash Flow |
(51.63) | (36.58) | (104.30) | (60.41) | (100.37) | (110.00) | (86.60) | 74.30 | (148.97) | (116.16) |
Working Capital |
44.19 | 82.07 | 52.51 | 48.29 | 114.55 | 196.17 | 306.85 | 164.58 | 54.59 | 137.61 |
Capital Expenditures |
(0.13) | (0.35) | (0.57) | (0.33) | (0.28) | (0.28) | (0.11) | (0.43) | (0.16) | (0.06) |
Net Current Asset Value |
(44.46) | (10.77) | (106.22) | (142.24) | (150.51) | (147.53) | (62.05) | (185.35) | (325.57) | (231.20) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.25 | 0.26 | 0.25 | 0.47 | 0.63 | 0.80 | 1.86 | 1.42 | (1.07) | (0.38) |
Cash ROIC |
(58.94%) | (22.20%) | (94.64%) | (53.23%) | (39.47%) | (22.01%) | (14.53%) | 20.64% | (156.63%) | (44.83%) |
Accounts Receivable Turnover |
4.49 | 4.44 | 1.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.32 | 0.23 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
1.77 | 1.37 | 1.93 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
651.16 | 2,265.51 | 4,477.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
291.59 | 150.00 | 62.73 | 0.00 | 306.05 | 0.00 | 0.00 | — | — | — |
Average Receivables |
9.28 | 14.59 | 19.98 | 29.00 | 19.51 | 21.00 | 125.69 | 110.66 | 7.92 | 9.33 |
Average Payables |
4.47 | 4.61 | 6.49 | 5.80 | 4.76 | 8.80 | 9.69 | 6.85 | 6.81 | 5.33 |
Average Inventory |
0.80 | 0.79 | 0.27 | 0.62 | 1.25 | — | — | — | — | — |
Average Assets |
58.14 | 91.80 | 106.13 | 116.45 | 159.01 | 300.16 | 505.12 | 484.62 | 327.67 | 301.36 |
Average Common Equity |
(31.84) | (20.13) | (51.48) | (104.59) | (114.89) | (48.49) | 54.73 | 30.35 | (103.80) | (151.92) |
Columns are period end dates